Walleye Trading
PGNX

Walleye Trading’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Walleye Trading’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-34,045
Closed -$154K – 5037
2018
Q4 		$143K Buy
34,045
+12,652
+59% +$64.4K ﹤0.01% 3670
2018
Q3 		$134K Sell
21,393
-3,106
-13% -$23.9K ﹤0.01% 4039
2018
Q2 		$197K Buy
+24,499
New +$187K ﹤0.01% 3659
2018
Q1 		– Sell
-8,448
Closed -$50 – 4953
2017
Q4 		$50 Buy
+8,448
New +$51.3K ﹤0.01% 4020
2017
Q2 		– Sell
-1,800
Closed -$17 – 5175
2017
Q1 		$17 Sell
1,800
-6,200
-78% -$61.9K ﹤0.01% 4197
2016
Q4 		$69K Buy
+8,000
New +$59.1K ﹤0.01% 3474
2015
Q4 		– Sell
-6,200
Closed -$35K – 5912
2015
Q3 		$35K Buy
+6,200
New +$47.6K ﹤0.01% 3754

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Walleye Trading's PGNX Position: Q1 2019 in Review

Walleye Trading sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2019, closing a stake of 34,045 shares — an estimated $154K sold.

Walleye Trading first reported a position in PGNX in Q3 2015 and held it in 7 quarters. The position peaked at $197K in Q2 2018. 148 funds tracked by Wall St. Rank hold PGNX as of Q1 2019.

  • Walleye Trading reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2019 after selling out during the quarter.
  • Walleye Trading sold 34,045 Progenics Pharmaceuticals Inc shares in Q1 2019, an estimated $154K.
  • Walleye Trading first reported a position in Progenics Pharmaceuticals Inc in Q3 2015 and held it in 7 quarters.
  • Walleye Trading's Progenics Pharmaceuticals Inc position peaked at $197K in Q2 2018.
  • 148 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2019.

Based on Walleye Trading's 13F filing for Q1 2019, filed 15 May 2019.